CN119546299A - Tyk2抑制剂及其用途 - Google Patents

Tyk2抑制剂及其用途 Download PDF

Info

Publication number
CN119546299A
CN119546299A CN202380030453.6A CN202380030453A CN119546299A CN 119546299 A CN119546299 A CN 119546299A CN 202380030453 A CN202380030453 A CN 202380030453A CN 119546299 A CN119546299 A CN 119546299A
Authority
CN
China
Prior art keywords
patient
compound
disease
administration
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380030453.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·纳恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arumis Inc
Original Assignee
Arumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arumis Inc filed Critical Arumis Inc
Publication of CN119546299A publication Critical patent/CN119546299A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380030453.6A 2022-03-29 2023-03-29 Tyk2抑制剂及其用途 Pending CN119546299A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263324754P 2022-03-29 2022-03-29
US63/324,754 2022-03-29
US202263344126P 2022-05-20 2022-05-20
US63/344,126 2022-05-20
US202263408572P 2022-09-21 2022-09-21
US63/408,572 2022-09-21
US202263429720P 2022-12-02 2022-12-02
US63/429,720 2022-12-02
PCT/US2023/016677 WO2023192351A1 (en) 2022-03-29 2023-03-29 Tyk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN119546299A true CN119546299A (zh) 2025-02-28

Family

ID=86142785

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380030453.6A Pending CN119546299A (zh) 2022-03-29 2023-03-29 Tyk2抑制剂及其用途

Country Status (11)

Country Link
US (1) US20250205211A1 (cg-RX-API-DMAC10.html)
EP (1) EP4499092A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025510311A (cg-RX-API-DMAC10.html)
KR (1) KR20240166011A (cg-RX-API-DMAC10.html)
CN (1) CN119546299A (cg-RX-API-DMAC10.html)
AU (1) AU2023245329A1 (cg-RX-API-DMAC10.html)
CA (1) CA3246725A1 (cg-RX-API-DMAC10.html)
IL (1) IL315866A (cg-RX-API-DMAC10.html)
MX (1) MX2024011860A (cg-RX-API-DMAC10.html)
TW (1) TW202342000A (cg-RX-API-DMAC10.html)
WO (1) WO2023192351A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121909018A (zh) * 2023-09-20 2026-04-21 阿鲁米斯公司 Tyk2抑制剂的立即释放制剂
WO2026136251A1 (en) * 2024-12-16 2026-06-25 Alumis Inc. Tyk2 inhibitor for treating neuroinflammatory or neurodegenerative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
US20230295119A1 (en) * 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines

Also Published As

Publication number Publication date
MX2024011860A (es) 2024-11-08
KR20240166011A (ko) 2024-11-25
TW202342000A (zh) 2023-11-01
CA3246725A1 (en) 2023-10-05
US20250205211A1 (en) 2025-06-26
IL315866A (en) 2024-11-01
WO2023192351A1 (en) 2023-10-05
EP4499092A1 (en) 2025-02-05
AU2023245329A1 (en) 2024-10-10
JP2025510311A (ja) 2025-04-14

Similar Documents

Publication Publication Date Title
US20120053189A1 (en) Btk inhibitors for the treatment of immune mediated conditions
Hehir et al. Diagnosis and management of myasthenia gravis
US20180117148A1 (en) Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
JP7564347B2 (ja) 多発性硬化症を治療するためのｌｏｕ０６４
WO2021128027A1 (zh) TACI-Fc融合蛋白及其用途
US20250205211A1 (en) Tyk2 inhibitors and uses thereof
US20060083714A1 (en) Combination of a pde iv inhibitor and a tnf-alpha antagonist
TW202345799A (zh) Ｔｙｋ２抑制劑及其用途
WO2025027388A1 (en) Obefazimod for treatment of ulcerative colitis
Zhao et al. The off-label uses profile of tofacitinib in systemic rheumatic diseases
US20260027116A1 (en) Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
TWI922445B (zh) 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈治療天皰瘡之方法
WO2025090702A1 (en) Rilzabrutinib for use in the treatment of itch associated with atopic dermatitis and/or prurigo nodularis
JP2026510948A (ja) 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法
US20250170158A1 (en) Methods of treating medical conditions using censavudine or a related compound
WO2025111752A1 (zh) 以Lck/Fyn介导STAT3磷酸化为靶点的阻断剂和生物材料的用途
AU2023393624A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
WO2024041633A1 (zh) 一种稠环嘧啶类化合物的用途
AU2021221333A1 (en) Novel medicament for treating inflammatory disease
CN110804642A (zh) Gpr174免疫学功能及其用途
US20240285563A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis
CN117396204A (zh) 使用s-羟氯喹治疗抗磷脂综合征
CN118019540A (zh) 用于治疗多发性硬化的lou064
CN121909018A (zh) Tyk2抑制剂的立即释放制剂
HK1102405A1 (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination